A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation

Lise J Estcourt; Gemma L Crighton; Erica M Wood; Simon Stanworth; Marialena Trivella; Carolyn Doree; Alan Tinmouth; Michael F Murphy

doi:10.1002/14651858.CD010981

A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation

Cochrane Database Syst Rev. 2014:(3):CD010981. doi: 10.1002/14651858.CD010981.

Authors

Lise J Estcourt¹, Gemma L Crighton², Erica M Wood³, Simon Stanworth¹, Marialena Trivella⁴, Carolyn Doree⁵, Alan Tinmouth⁶, Michael F Murphy⁷

Affiliations

¹ Haematology/Transfusion Medicine, NHS Blood and Transplant, Oxford, UK.
² Clinical Haematology, Royal Children' s Hospital Melbourne, Melbourne, Australia.
³ Department of Clinical Haematology, Monash University, Melbourne, Australia.
⁴ Centre for Statistics in Medicine, University of Oxford, Oxford, UK.
⁵ Systematic Review Initiative, NHS Blood and Transplant, Oxford, UK.
⁶ Medicine (hematology) and Pathology Centre for Transfusion Research, The Ottawa Health Research Institute and the University of Ottawa, Ottawa, Canada.
⁷ NHS Blood and Transplant, John Radcliffe Hospital, Oxford, UK.

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows: To determine whether a therapeutic-only platelet transfusion policy (platelet transfusions given when patient bleeds) is as effective and safe as a prophylactic platelet transfusion policy (platelet transfusions given to prevent bleeding usually when the platelet count falls below a given trigger level) in patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation.

Abstract

Grants and funding